Structure TherapeuticsGPCR
Recorded

Structure Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongAnalyst

All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, covering analyst for small-cap biotech in the U.S. It is my pleasure to have the fireside chat with Structure Therapeutics. We have the CEO, Ray Stevens, and we have CFO, Jun Yoon.

Raymond StevensCEO

Welcome, gentlemen. Thank you, Roger.

Raymond StevensCEO

Thank you for having us here, and also thank you for organizing the investor dinner last night. That was a lot of fun.

Roger SongAnalyst

It was. All right. Maybe, Ray, if you may, just give us some state of the union of Structure, particularly you have two major pillars of the obesity franchise, and where they are, and why you are excited about them at the high level, and we can drill down to the details.

Raymond StevensCEO

Yeah, absolutely, Roger. It is remarkable the sort of journey that Structure has been on for a number of years. The current status, we now have two phase III trials that are currently ongoing, ACCOMPLISH-1 and ACCOMPLISH-2. ACCOMPLISH-1 is for those individuals that are overweight, and ACCOMPLISH-2 are individuals overweight with type 2 diabetes. Those two programs are currently enrolling, and that data will read out at the end of 2028. The second study that is also right now ongoing, it is in a phase IIa, is our amylin, ACCG-2671. We shared MAD SAD data back in September, and now the 12-week MAD data is currently ongoing.

Roger SongAnalyst

Excellent. The amount of the attention you get from investors, and then also the question I got from investors is mostly on the amylin side. Maybe we can focus more on the amylin first and then see how much time we want to spend on that, and then we can also definitely going to talk about Aleni, which is in the phase III, as you already stated. For the amylin, you reported the phase I SAD data, and then you decided to quickly move into the MAD 12-week in obesity patient. What should we expect to see in the MAD at the broad stroke, and then I have a couple detailed questions related to that.

Raymond StevensCEO

Yeah. A couple of things, just as sort of a reminder. We shared SAD, single ascending dose data, back in September. The dose range that we looked at was from one milligram to 10 milligrams. This is a very potent molecule, which has me excited because one of the things I'm really focused on is cost of goods. We think that we have a very unique molecule in terms of potency, in terms of the potential cost of goods for this. Second thing that came from that dataset was the half-life. It's a six-day half-life, and this gives us a lot of optionality. What I like about that is that in many ways, it's a self-titrating molecule. For example, we saw in that SAD data, at one and two milligrams, we saw absolutely no AEs whatsoever.

Raymond StevensCEO

As you take the first dose, I give you one dose, one milligram. The next day, I give you a second dose, your dosage is one.X, a little bit more, because it is accumulating very, very slowly. We think this is important in this class of medicines, that it's essentially a self-titrating mechanism that we're really taking advantage of. We like that. Going to your question about the multiple ascending dose- This is a 12-week study.

Raymond StevensCEO

What we're going to be looking for, first of all, is safety and understanding further pharmacokinetics, and in particular, understanding the accumulation of the ACCG-2671. Second, we'll be looking for efficacy as measured by body weight loss. Then third, we are quite curious about combinability, and so we have an additional arm in this study where individuals that are on an injectable GLP-1, if they take this on top of that, are the effects additive? We'll be looking at all those things in the multiple ascending dose study. But really, the goal is to further characterize the titration in a 12-week time period in those regards.

Roger SongAnalyst

Excellent. I think we should say that earlier your ACCG-2671 is the first-in-class small molecule amylin, because we know we have a couple peptide amylin already in study and then later stage as well. Based on your SAD data, I think you stated it as well, it is a peptide-like small molecule, and then with the long half-life and then the potency. The question become, because you are first in class, what could be the right benchmark? Which amylin we should benchmark, and then maybe even the incretin side?

Raymond StevensCEO

Yeah, Roger, thank you for clarifying that as well. With the six-day half-life, I remember a few years ago, people, many of my friends and colleagues in the pharmaceutical industry, they are like, "Ray, you can never make a small molecule to amylin." The RAMP combined with calcitonin, the complexity of the system, the equilibria, and everything. I am really, really proud of our chemist, our biologist, what they have been able to accomplish. With that six-day half-life, this is a small molecule that really behaves just like a peptide. That, I think, is quite unique. I think that is something that is going to be important.

Raymond StevensCEO

In terms of benchmark, when we designed the molecule, and again, we designed this, we have been working on GLP-1 and amylin for, I have been working on it for 30 years, amylin really hard for 10 years. We used cagrilintide as our original benchmark that had the most human data. Cagrilintide was the first. Now we use cagrilintide, petrelintide, eloralintide as the right benchmarking set. We think that the 12-week data, we need to be, for this small molecule to be viable, it needs to be in the same range as the injectable peptides. As you said, this is the first oral amylin small molecule, and we feel the need to try to get this approved as fast as possible. Everything that we are doing is to try to accelerate the clinical development of this molecule.

Raymond StevensCEO

We have, just as an additive to your question, Roger.

Raymond StevensCEO

Sure we have another molecule, ACCG-3535, that will be going into the clinic by the end of this year, and that is another DACRA as well.

Roger SongAnalyst

Yeah, that is right. You mentioned this DACRA because you mentioned three drugs, cagrilintide, petrelintide, and then eloralintide. Two of them are DACRA, and then eloralintide is more lean towards SERA. We can debate that. But on the other side is that the spectrum of the weight loss you are thinking about within that zip code, injectable amylin, between those three drugs.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day